The effect of addition of calcipotriol ointment (50 μg/g) to acitretin therapy in psoriasis

British Journal of Dermatology

Volumn 138, Issue 1, 1998, Pages 84-89

  Van De Kerkhof, P C M ^a   Cambazard, F ^b   Hutchinson, P E ^c   Haneke, E ^d   Wong, E ^e   Souteyrand, P ^f   Damstra, R J ^g   Combemale, P ^h   Neumann, M H A M ⁱ   Chalmers, R J G ^j   Olsen, L ^k   Revuz, J ^l  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Service de Dermatologie   (France)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d HELIOS KLINIKUM WUPPERTAL   (Germany)

^e ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^f HÔTEL DIEU   (France)

^g NIJ SMELLINGHE HOSPITAL   (Netherlands)

^h HIA Desgenettes   (France)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j HOPE HOSPITAL   (United Kingdom)

^k LEO PHARMA A S   (Denmark)

^l HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; ETRETIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACITRETIN; ADULT; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS; TREATMENT OUTCOME;

EID: 6844260549     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1998.02030.x     Document Type: Article

References (20)

1. Saurat JH. Side effects of systemic retinoids ami their clinical management. J Am Acad Dermatol 1992; 27: 23-8.
2. Gollnick H, Bauer R,. Brindley C et al. Acitretin versus etretinate in psoriasis. J Am Acad Dermatol 1988; 19: 458-69.
3. Kragballe K, Jansen CT, Geiger JM et al. A double blind comparison of acitretin and etretinatein the treatment of severe psoriasis. Acta Derm Venerol (Stockh) 1989; 69: 35-40.
4. Saurat JH, Geiger JM, Amhlard P et al. Randomized double blind multicentre study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica 1988; 177: 218-24.
5. Orfanos CE, Steigleder GK, Pullman H et al. Oral retinoid and UVB radiation. Acta Derm Venerol (Stockh) 1979; 59: 241-4.
6. Binderup L, Bramin E, Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 1988; 27: 889-95.
7. 3 analogue stimulates differentiation and inhibits proliferation of cultured human keratinocytes. J Invest Dermatol 1988; 91: 383.
8. 3 analogue (MC903) in a double blind study. Br J Dermatol 1988; 119: 223-30.
9. 3 analogue (MC903) in double blind study. Arch Dermatol 1989; 125: 1647-52.
10. Cunliffe WJ, Berth-Jones J, Claudy A et al. Comparative study of calcipotriol (MC903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1942; 26: 736-43.
11. Kragballe K, Tore Gjertsen B, de Hoop D et al. Double blind right/left comparison of calcipotriol and betamethasone valerate in the treatment of psoriasis vulgaris. Lancet 1991; 337: 195-6.
12. van de Kerkhof PCM. Dithranol treatment for psoriasis. After 75 years still going strong. Eur J Dermatol 1991; 1: 79-89.
13. Grossman RM, Thivolet J, Claudy A et al. A novel therapeutic approach to psoriasis: combination calcipotriol ointment and very low dose cyclosporin. J Am Acad Dematol 1994; 31: 68-70.
14. Frappaz A, Thivolet J. Calcipotriol in combination with PUVA. A randomized double blind placebo study in severe psoriasis. Eur J Dermatol 1993; 3: 364-7.
15. Ramsay CA, Berth-Jones J, Brundin G et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994; 189: 260-4.
16. Frederiksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
17. Carlberg C, Bendik I, Wyss A et al. Two nuclear signalling pathways for vitamin D. Nature 1993; 361: 657-60.
18. Carlberg C. The vitamin D 3 receptor in the context of the nuclear receptor superfamily. The central role of retinoid X receptor. Endocrine 1996; 4: 91-105.
19. 3 in mouse immortalized osteoblastic C1 cells. Am J Physiol 1994; 266: 1247-56.
20. van de Kerkhof PCM. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol 1995; 132: 675-82.